Cyclopentolate Hydrochloride

Ophthalmic examination requires a dilated pupil and a temporarily paralysed ciliary muscle, and cyclopentolate hydrochloride provides both. Applied as eye drops, the agent blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body, producing mydriasis together with cycloplegia, the loss of accommodation that permits accurate refraction. Compared with atropine, onset is faster and duration considerably shorter, which limits the period of blurred near vision after an examination. The salt form is the standard presentation for topical ocular use, and the antimuscarinic mechanism is shared with atropine even though the kinetics differ. Chemically it is C17H26ClNO3 with a molecular weight of about 327.8 g/mol, approved and developed through the final clinical phase.

SMILES

CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1.Cl

InChI

InChI=1S/C17H25NO3.ClH/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17;/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3;1H